Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Toward A Vaccine for AIDS: The Emergence of Immunobiology-Based Vaccine Development

Toward A Vaccine for AIDS: The Emergence of Immunobiology-Based Vaccine Development Over a decade has passed since the identification of the human immuno­ deficiency virus (HIV) as the causative agent of AIDS. During this time, HIV has been extensively characterized, and a variety of vaccine constructs and strategies have been explored. For the most part, these have been driven by successes of the past with other pathogens, or by novel approaches enabled by technologies of the present. With the maturing of our insights into the immunopathology of HIV and basic immunological mechanisms, we are presented with unprecedented opportunities to ration­ ally develop vaccine approaches strategically designed to counter the immunopathology of HIV. As opposed to absolute prevention of infection, the primary goal of these strategies may be to limit infection and to assure a response to infection that prevents disease and transmission. Thus, such vaccines may find utility in both preventive and therapeutic roles. In this I The US government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper. CEASE & BERZOFSKY paper, we present the background and current state of immunobiology­ driven vaccine development for AIDS. INTRODUCTION Ever since the time of Jenner, the primary strategy applied to viral vaccine http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Immunology Annual Reviews

Toward A Vaccine for AIDS: The Emergence of Immunobiology-Based Vaccine Development

Annual Review of Immunology , Volume 12 (1) – Apr 1, 1994

Loading next page...
 
/lp/annual-reviews/toward-a-vaccine-for-aids-the-emergence-of-immunobiology-based-vaccine-v86xAw3YAW
Publisher
Annual Reviews
Copyright
Copyright 1994 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0732-0582
eISSN
1545-3278
DOI
10.1146/annurev.iy.12.040194.004423
pmid
7516670
Publisher site
See Article on Publisher Site

Abstract

Over a decade has passed since the identification of the human immuno­ deficiency virus (HIV) as the causative agent of AIDS. During this time, HIV has been extensively characterized, and a variety of vaccine constructs and strategies have been explored. For the most part, these have been driven by successes of the past with other pathogens, or by novel approaches enabled by technologies of the present. With the maturing of our insights into the immunopathology of HIV and basic immunological mechanisms, we are presented with unprecedented opportunities to ration­ ally develop vaccine approaches strategically designed to counter the immunopathology of HIV. As opposed to absolute prevention of infection, the primary goal of these strategies may be to limit infection and to assure a response to infection that prevents disease and transmission. Thus, such vaccines may find utility in both preventive and therapeutic roles. In this I The US government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper. CEASE & BERZOFSKY paper, we present the background and current state of immunobiology­ driven vaccine development for AIDS. INTRODUCTION Ever since the time of Jenner, the primary strategy applied to viral vaccine

Journal

Annual Review of ImmunologyAnnual Reviews

Published: Apr 1, 1994

There are no references for this article.